Search
Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
ABBV-011
go.drugbank.com/drugs/DB18622InvestigationalABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Synonyms: an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicinCentanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that … [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention
Categories: Psychostimulants, Agents Used for ADHD and NootropicsSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Antineoplastic and Immunomodulating AgentsDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalThe cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]
Encainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnThe manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Pruritic Dermatitis
go.drugbank.com/conditions/DBCOND0032098Drugs: BenzocaineSynonyms: Pruritus and inflammation of skin, Pruritus and inflammation of skin (disorder)Acute Allergic Reactions
go.drugbank.com/conditions/DBCOND0080552Drugs: PromethazineSynonyms: Other and unspecified allergy, Atopic AND/OR hypersensitivity state